Antiparkinsonian agents and long‐term neuroleptic treatment: EFFECT OF G 31.406, ORPHENADRINE, AND PLACEBO ON PARKINSONISM, SCHIZOPHRENIC SYMPTOMS, DEPRESSION AND ANXIETY

Acta Psychiatrica Scandinavica

Volumn 55, Issue 4, 1977, Pages 251-260

  Gerlach, J ^a   Rasmussen, P T ^a   Hansen, L ^a   Kristjansen, P ^a  

^a Sct Hans Hospital   (Denmark)

Author keywords

Antiparkinsonian agents; G 31.406; long term neuroleptic therapy; orphenadrine; schizophrenia

Indexed keywords

AMANTADINE; CHLORPROTHIXENE; CLOZAPINE; FLUPHENAZINE; HALOPERIDOL; NEUROLEPTIC AGENT; ORPHENADRINE; PERPHENAZINE; PLACEBO; THIORIDAZINE;

ACCOMMODATION; ADVERSE DRUG REACTION; ANXIETY; CLINICAL STUDY; CONSTIPATION; DEPRAMINE; DEPRESSION; DRUG COMPARISON; DRUG THERAPY; EXTRAPYRAMIDAL SYMPTOM; MAJOR CLINICAL STUDY; ORAL DRUG ADMINISTRATION; ORTHOSTATIC HYPOTENSION; PARKINSONISM; SCHIZOPHRENIA; THERAPY; XEROSTOMIA;

ADMINISTRATION, ORAL; ADULT; AGED; ANTIPARKINSON AGENTS; ANXIETY; CLINICAL TRIALS; DEPRESSION; DIBENZAZEPINES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG EVALUATION; DYSKINESIA, DRUG-INDUCED; HUMAN; MIDDLE AGE; ORPHENADRINE; PARKINSON DISEASE; PLACEBOS; SCHIZOPHRENIA; TABLETS; TIME FACTORS; TRANQUILIZING AGENTS;

EID: 0017601615     PISSN: 0001690X     EISSN: 16000447     Source Type: Journal    
DOI: 10.1111/j.1600-0447.1977.tb00170.x     Document Type: Article

References (31)

1. Tolerance phenomena with neuroleptics. Catalepsy apomorphine stereotypies and striatal dopamine metabolism in the rat after single and repeated administration of loxapine and haloperidol
2. Neuroleptics and antiparkinsonian drugs
3. An inventory for measuring depression
4. Antiparkinsonian agents and depot phenothiazine
5. Drug‐induced extrapyramidal syndromes
6. Ein Beitrag zur Behandlung des Parkinson‐Syndroms
7. Antiparkinson drug overuse
8. Reversal of antiparkinsonian drug toxicity by physostigmine: A controlled study
9. Drugs for Parkinson's disease: Centrally acting muscle relaxants
10. Dopaminergic hypersensitivity and cholinergic hypofunction in the pathophysiology of tardive dyskinesia
11. The movement pattern of oral tardive dyskinesia in relation to anticholinergic and antidopaminergic treatment
12. Extrapyramidal reactions and amine metabolism in cerebrospinal fluid during haloperidol and clozapine treatment of schizophrenic patients
13. Benzhexol and side effects with long‐acting fluphenazine therapy
14. Persistence of extra‐pyramidal disorders and psychiatric relapse after withdrawal of long‐term phenothiazine therapy
15. Effect of cholinergic and anticholiiergic agents on tardive dyskinesia
16. Evaluating the long‐term need for antiparkinson drugs by chronic schizophrenics
17. Behavioral and electroencephalographic effects of atropine and related compounds
18. Comparison of amantadine, orphenadrine, and placebo in the control of phenothiazine‐induced Parkinsonism
19. Long‐term effect of neuroleptic drugs
20. Withdrawal of antiparkinson drugs
21. The brief psychiatric rating scale
22. The use of disipal in psychiatric treatment
23. Neuroleptic‐induced hypersensitivity of striatal dopamine receptors in the rat as a model of tardive dyskinesias. Effects of clozapine, haloperidol, loxapine and chlorpromazine
24. Acute and subacute effects of neuroleptics on dopamine synthesis and release in the rat striatum
25. A rating scale for extrapyramidal side effects
26. A comparative study of haloperidol and chlorpromazine in terms of clinical effects and therapeutic reversal with benztropine in schizophrenia. Theoretical implications for potency differences among neuroleptics
27. Phenothiazine‐induced decompensation